Human blood

Tender description

NHSBT requires pathogen reduced plasma which will then be subsequently manufactured into FFP, Single and pooled cryoprecipitate for paediatric and neonatal use, for recipients born on / after 1.1.1996. Those recipients are deemed not to have been exposed to the risk of vCJD in the UK food chain. Plasma is to be sourced from a TPSG approved (based on SaBTOs 2013 recommendations) country outside the UK with vCJD prevalence >2,5 log lower than the UK. The Contract commenced on the 8.5.2018, the term of this Contract shall expire 2 years from the end of the Set Up Period and Ramp Up Period 1.12.2018 (estimated). The contract is for a period of 2 years with the option to extend for 2 periods of 12 months. The estimated value given below is based on 4 years. NHSBT requires pathogen reduced plasma which will then be subsequently manufactured into FFP, Single and pooled cryoprecipitate for paediatric and neonatal use, for recipients born on / after 1.1.1996. Those recipients are deemed not to have been exposed to the risk of vCJD in the UK food chain. Plasma is to be sourced from a TPSG approved (based on SaBTOs 2013 recommendations) country outside the UK with vCJD prevalence >2,5 log lower than the UK.